European equities traded in the US as American depositary receipts were lower late Wednesday morning, declining 0.36% to 1,442.32 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and internet browser company Opera (OPRA), which rose 3.6% each. They were followed by 3D printer company Materialise (MTLS) and petroleum refiner Equinor (EQNR), which were up 2.2% and 1.9% respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which fell 2.5% and 2.1% respectively. They were followed by pharmaceutical companies Ascendis Pharma (ASND) and Novo Nordisk (NVO), which were down 1.8% and 1.3% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Akari Therapeutics (AKTX), which advanced 25% and 5% respectively. They were followed by biopharmaceutical company Amarin (AMRN) and cruise line operator Carnival (CUK), which increased 4.9% and 3.1% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and biotech firm Trinity Biotech (TRIB), which dropped 3.5% and 2.8% respectively. They were followed by pharmaceutical company GSK (GSK) and medical device maker Smith & Nephew (SNN), which lost 1.9% and 1.7% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.